(Total Views: 222)
Posted On: 10/04/2022 2:50:07 PM
Post# of 102825
Nascent Biotech, Inc. (OTCQB: $NBIO) ("Nascent Biotech", "Nascent", or the "Company"
, a clinical-stage biotechnology Company focused on the development of monoclonal antibodies targeting various cancer types, announced today that the Company has enrolled the first patient of the fifth and final cohort of its Phase I clinical trial to evaluate Pritumumab ("PTB" as a treatment for Primary and Metastatic Brain Cancers.
https://finance.yahoo.com/news/nascent-begins...00290.html
, a clinical-stage biotechnology Company focused on the development of monoclonal antibodies targeting various cancer types, announced today that the Company has enrolled the first patient of the fifth and final cohort of its Phase I clinical trial to evaluate Pritumumab ("PTB" as a treatment for Primary and Metastatic Brain Cancers. https://finance.yahoo.com/news/nascent-begins...00290.html
(0)
(0)
